The 271-Day Pig Kidney Changes the Xenotransplant Math
A pig kidney functioned for 271 days in a human patient before failing — the longest-recorded xenotransplant. The case doesn't just break a durability record; it reshapes how doctors will deploy pig organs in a crisis where thousands die waiting.
The 271-Day Mark Changes Everything
Tim Andrews needed a kidney. He was 66, suffering from end-stage renal disease caused by type 2 diabetes, and the waitlist said seven years — a sentence most people on dialysis don’t survive.
In January 2025, surgeons at Mass General Brigham attached a genetically modified pig kidney to his blood vessels. It worked immediately. It kept working for 271 days — the longest a pig organ has ever functioned inside a human body. Then it failed, not from classic rejection, and Andrews returned to dialysis for another 82 days before receiving a human donor kidney in January this year.
The case, published in the Lancet, is not a triumph. But it is something rarer: proof of concept that xenotransplantation can buy time. And in a system where roughly 100,000 Americans and more than 7,000 Britons are waiting for kidneys that simply do not exist in sufficient numbers, time is the only currency that matters.
The Biology Behind the Breakthrough
You cannot take a kidney from a farm pig and put it into a person. The human immune system would identify it as foreign within minutes, launching an assault that turns the organ black as cells rupture and clot forms inside the tissue.
The solution was years of genomic editing. The Yucatan miniature pig that donated Andrews’ kidney carried 69 modifications designed to humanise its organs. Some edits stripped out pig cell features that trigger immune recognition. Others inserted human DNA sequences that act as camouflage, blurring the line between self and non-self. Additional tweaks disabled retroviruses hidden in the pig genome that could otherwise jump species and infect the recipient.
This is not science fiction. It is the result of a research programme that has been quietly refining these modifications for well over a decade, with each generation of pigs carrying fewer of the triggers that would provoke a catastrophic rejection response.
When the pig kidney was transplanted, Andrews’ immune system showed early signs of fighting back. Doctors adjusted his immunosuppressant medication and held the line. For nearly nine months, the organ filtered his blood without the need for dialysis — giving him something he described as hope, a chance to live outside a hospital schedule.
Why It Failed — and Why That Matters
By around the six-month mark, the blood vessels inside the kidney began to show damage. Inflammation set in. The organ started to fail.
Here is the critical detail: there were no antibodies attacking the pig tissue. This was not classical antibody-mediated rejection, the kind that typically dooms xenografts within days or weeks. Something else was happening — an unknown mechanism of vascular injury that researchers have yet to fully explain.
That ambiguity is both a problem and an opportunity. If doctors can identify the cause, they may be able to prevent it. The fact that the organ lasted 271 days at all suggests the immune barrier has been meaningfully lowered. The remaining failure mode is likely a solvable one, or at least a tractable one.
Dr Leonardo Riella, who led the transplant team, framed it plainly. “We are in a crisis,” he said, referring to the organ shortage. Xenotransplantation, he argued, could become an alternative for patients without living donors — potentially bypassing dialysis entirely and buying time until a human organ becomes available.
The Math of Desperation
The numbers behind this case are brutal. In the United States, about 25,000 kidney transplants are performed annually. One hundred thousand people are on the waitlist. The average survival on dialysis is five years. Andrews was told he might not make it to the top of the list.
In the UK, more than 7,000 people are waiting for a kidney. Similar proportions apply in other wealthy nations with mature transplant systems. The gap between supply and demand is not a marginal shortfall. It is structural.
This is why the 271-day result matters beyond the clinic. It demonstrates that a pig kidney can serve as a bridge — a functional interim organ that carries a patient through the waiting period until a human donor kidney appears. Andrews received his human transplant roughly nine months after the xenograft failed. Without the pig kidney, he would have spent those nine months on dialysis, with all the health risks and mortality risk that entails.
The question now is not whether xenotransplantation can work. It is how long the bridge can be made to last, and how many patients can cross it before a donor arrives.
Who Wins, Who Loses
Patients on dialysis lists win the most. For them, the difference between a pig kidney and no kidney at all is the difference between months of hospital visits and a return to something resembling normal life. Andrews described the transplanted organ as the light at the end of the tunnel. That language is not clinical. It is urgent.
Pharmaceutical and biotech companies developing gene-edited pig lines also stand to gain. The commercial pipeline around xenotransplantation is expanding, and every successful case strengthens the investment thesis.
What is less clear is who loses. If pig organs become widely available, they could displace some human organ allocation, potentially creating ethical tension around prioritisation. There are also unresolved questions about long-term safety — not just for the recipient, but for anyone exposed to genetically modified organisms in a clinical setting. The retroviral safety work is promising, but the track record of xenotransplantation in humans remains exceptionally short.
What Comes Next
The Mass General Brigham team has turned this single case into a roadmap. The next steps involve replicating the result with longer graft survival, identifying the vascular damage mechanism, and expanding the programme to other organ types. Liver and heart xenotransplants have already been attempted in a handful of patients, with far shorter survival times. A kidney that lasts nine months is not a dead end — it is a foundation.
The 271-day milestone does not mean pig organs are ready to replace human donors. It means they are ready to complement them, to fill the gap that dialysis leaves behind and that the current transplant system cannot close. For Andrews, the pig kidney was not the destination. It was the bridge. The question now is whether that bridge can be made long enough for the patients who need it most.